Companies website is new 2014, but appears to be around since 2007..
FIB, it's what Gino is also trying to achieve, but Gino's readout system is not just locked to the biomedical sector. It's harder and takes a long time to get things through into medical areas.
But then again, it's just intellectual property as PSY's which ain't worth crap till it's a marketed product... Whether it hinders PSY? Doubt it!!! many players enter various marketed arena's it's called competition.
WOBURN, Mass.--(BUSINESS WIRE)--Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of sensor products in the medical field, including portable and cost-effective detectors for infectious diseases such as HIV. Alpha Szenszor’s co-founders include Steve Lerner, an industry veteran with over 28 years of product development and industrialization experience, and Professor Charles Lieber of Harvard University, world-renowned expert in the field of nanobio sensors.
“The Nantero technology provides a highly industrialized platform through which my years of work may be applied to facilitate this revolution in global health care.”
Nantero’s intellectual property includes over 100 patent applications, of which over 25 have already been granted. This intellectual property portfolio is centered around the use of carbon nanotubes in mass manufacturing environments to make a variety of products, including Nantero’s NRAM™, a high-density nonvolatile random access memory device. In addition to its work developing NRAM, Nantero is actively licensing its intellectual property portfolio to both startups and established companies for the development of other products that incorporate carbon nanotubes.
Alpha Szenszor is developing a biomedical sensor platform for applications in the field of disease diagnostics and personalized medicine. These products will allow testing of a wide range of diseases such as Cold and Flu, Cancer, Heart Disease, Sexually Transmitted Infections, Food Contamination, and the presence of other life threatening disorders. Alpha Szenszor technology will eliminate the costly and time consuming procedures associated with current diagnostics technology.
Steve Lerner, CEO and Co-Founder of Alpha Szenszor, said, “With our world-class team combining experts in health care, semiconductor processing, and Nantero’s scalable carbon nanotube technology, we are poised to bring revolutionary products to market in a very short time frame. We will enable portable disease testing that would be available through local pharmacies and allow anyone to test themselves with total privacy and at a low cost. When placed in the hands of the primary care physicians, we envision our technology becoming part of every patient check-up.”
Professor Charles Lieber, Co-Founder of Alpha Szenszor, added, “The Nantero technology provides a highly industrialized platform through which my years of work may be applied to facilitate this revolution in global health care.”
Greg Schmergel, CEO and Co-Founder of Nantero noted “Nantero is approached frequently for licenses to its intellectual property for various fields of use, and we have to pick carefully the right partners who have the capability to bring products to market that will add substantial value to their customers. We believe Alpha Szenszor is such a partner and look forward to working with them.”
About Nantero
Nantero is a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices. Nantero’s main focus is the development of NRAM™. Nantero is also working with licensees on the development of additional applications of Nantero’s core nanotube-based technology.
More information on Nantero, Inc. is available in English and Japanese at www.nantero.com
About Alpha Szenszor
Alpha Szenszor a point of care molecular diagnostics chip company. Alpha Szenszor’s products allow real time, label free detection and quantification of proteins and nucleic acids in a highly scaleable and cost effect platform. Most importantly the company ushers in a digital alternative to current optically based diagnostics. Alpha Szenszor is in the process of raising series A funds, and has already garnered the endorsement of several industry leaders.
Contacts
Nantero, Inc. Suzanne Gibbons-Neff, 617-670-1763
PSY Price at posting:
5.0¢ Sentiment: Hold Disclosure: Held
